| Payer perspectives on pharmacogenomics testing and drug development. | |
| | |
MedLine Citation:
|
PMID: 19102724 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A series of questions about hypothetical drugs and pharmacogenomic tests was posed to a panel of representatives from the health plan, government and employer sectors in order to elicit suggestions for input on data or study design considerations important for coverage determination. The panel suggested seven areas for drug developers to strongly consider. These areas were to include comparative information on new tests versus usual care, assess the negative predictive value of new tests, measure and report on cost offsets, balance relative risk improvement with absolute risk, consider the policy implications of the products or tests, report percentage responders in addition to group mean improvements, and to include specific pharmacogenomic information in US FDA approved labels. The panel was generally enthusiastic about the promise of the field to improve drug selection or dosing. |
| | |
Authors:
|
Robert S Epstein; Felix W Frueh; Dawn Geren; Doris Hummer; Scott McKibbin; Susan O'Connor; Gurvaneet Randhawa; Benjamin Zelman |
Related Documents
:
|
2186274 - The effect on test ordering of informing physicians of the charges for outpatient diagn... 19201934 - The unbearable lightness of diagnostic testing: time to contain inappropriate test orde... 8671134 - Factors predicting differences among general practitioners in test ordering behaviour a... 17043904 - Adherence of academic geriatric practitioners to osteoporosis screening guidelines. 12187024 - A simplified screening for alpha-thalassemia 1 (sea type) using a combination of a modi... 12269654 - Recurrence of allergic rhinitis, previously alleviated with allergen immunotherapy, aft... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pharmacogenomics Volume: 10 ISSN: 1744-8042 ISO Abbreviation: Pharmacogenomics Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2008-12-23 Completed Date: 2009-03-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897350 Medline TA: Pharmacogenomics Country: England |
Other Details:
|
Languages: eng Pagination: 149-51 Citation Subset: IM |
Affiliation:
|
Medco Health Solutions, Inc., 100 Parsons Pond Drive, Franklin Lakes, NJ 07417, USA. robert_epstein@medco.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cost-Benefit Analysis Diagnostic Techniques and Procedures / economics*, standards Drug Design* Humans Pharmaceutical Preparations / economics*, standards Pharmacogenetics / economics*, standards Predictive Value of Tests Reimbursement Mechanisms* United States United States Food and Drug Administration |
| Chemical | |
Reg. No./Substance:
|
0/Pharmaceutical Preparations |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what...
Next Document: Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast diff...